Does Wegovy help with visceral fat reduction?

What is visceral fat, and why does it matter more than the number on the scales?

Body fat is not a single thing. The layer of fat you can pinch under the skin (subcutaneous fat) behaves quite differently from the fat tucked deep in the abdominal cavity around your liver, kidneys, intestines and pancreas. That deeper store is visceral fat, and it is far more metabolically disruptive. It releases inflammatory signals, interferes with insulin sensitivity, and is more strongly associated with type 2 diabetes, fatty liver disease, cardiovascular disease and hypertension than subcutaneous fat at the same body weight.

This matters for anyone asking about whether Wegovy helps with belly fat, because not all belly fat is the same. A person can lose meaningful visceral fat and see their metabolic risk fall even before the bathroom scales move as much as they expected. Conversely, weight loss that comes mainly from muscle or subcutaneous fat does relatively little for the inflammatory and hormonal disruption driven by the visceral store. The distinction is not academic. It shapes whether weight-loss treatment actually reduces disease risk, or simply changes appearance.

Imaging studies using MRI and DEXA scans have been used in a number of GLP-1 trials precisely to tease apart which fat compartment is responding to treatment, and the results for semaglutide are instructive.

Does the trial evidence show visceral fat falling specifically on Wegovy?

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity or overweight and at least one weight-related condition to semaglutide 2.4 mg or placebo for 68 weeks. The headline result (roughly 15% average body-weight reduction on semaglutide versus around 2.4% on placebo) is widely cited. Less quoted are the body-composition analyses, which found that visceral fat fell substantially and in greater proportion than total fat mass in the semaglutide group.

Sub-studies and imaging analyses from the STEP programme consistently show that people using semaglutide lose a higher share of their abdominal visceral store than their overall fat loss would predict by proportionality alone. That pattern is relevant to risk: reductions in visceral fat are associated with improvements in insulin resistance, liver-fat content, blood pressure and lipid profiles, and these were reflected in the secondary endpoints of the STEP trials.

For those interested in the proportional visceral fat reduction figures from the semaglutide trials, they vary by study duration and starting composition, so they are worth reading in context rather than taken as a single headline number. The mechanism behind the preferential visceral response is not completely settled, but GLP-1 receptors are expressed in tissues involved in visceral fat regulation, and the appetite suppression semaglutide produces tends to shift people towards a caloric deficit that the body draws on visceral stores to fill.

Who can access Wegovy, and what does the consultation involve?

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE's appraisal of semaglutide, TA875, recommends it for up to two years within a specialist weight management service, for people with a BMI of 35 or above and at least one comorbidity, though private prescribing follows the licensed criteria, which are broader.

A prescriber reviews the full clinical picture before approving treatment: medical history, current medicines, contraindications and whether a weight management medicine is the right tool for this person at this point. BMI alone is never enough. If you have been thinking about whether treatment might suit you, a free consultation is the starting point, there is no obligation, and the assessment is completed the same day by a GPhC-registered Independent Prescriber rather than automated software.

Take-up tends to cluster around the start of a new month or just after payday, which is worth knowing if you want a faster turnaround, orders placed by midday on a weekday, once clinically approved, are dispatched the same day and delivered free the next working day. You can read more about how semaglutide works as a GLP-1 receptor agonist, or explore the Wegovy overview for a broader picture of the treatment, including the recently approved 7.2 mg dose. Our clinical team is available seven days a week if you have questions before or after you start.

What does this mean for someone considering Wegovy for metabolic health, not just weight?

The visceral fat question is often asked by people who are less focused on a dress size and more concerned about what their weight is doing to their liver, their blood sugar or their heart. That framing is clinically sound. The improvements in HbA1c, triglycerides and blood pressure seen in the STEP trials are consistent with visceral fat being a key target of semaglutide's effect, and they appeared alongside (sometimes ahead of) the weight-loss numbers.

The relationship between Wegovy and visceral fat is one of the more compelling aspects of the trial data, because it suggests the medicine may do more metabolic work than its weight-loss licence alone implies. Wegovy has since received UK authorisation for reducing cardiovascular event risk in eligible adults, and a conditional approval in July 2026 for a form of fatty liver disease (MASH), both of which are plausibly connected to its effects on visceral adiposity. The NHS guidance on semaglutide covers the mechanism and safety profile in plain language and is worth reading alongside any clinical consultation.

If the question of visceral fat reduction is central to why you are considering Wegovy, that is exactly the kind of thing to raise during a consultation. A prescriber can help you think through what the evidence means for your specific situation and whether treatment fits your health picture.